(Q35079157)

6 August 2017

0 references

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report (English)

1 reference

6 August 2017

1 reference

1 reference

Angelika Bezan

1

1 reference

6 August 2017

Florian Hohla

series ordinal

2

1 reference

6 August 2017

Thomas Meissnitzer

series ordinal

3

1 reference

6 August 2017

Richard Greil

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

31 December 2013

1 reference

6 August 2017

1 reference

6 August 2017

volume

13

1 reference

6 August 2017

page(s)

618

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-13-618

6 August 2017

exact match

0 references

cites work

Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3880167

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24380380

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24380380

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24380380

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-13-618

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference

6 August 2017

1 reference